Rasna Therapeutics Financials
| RASP Stock | USD 0 0 900.00% |
Rasna |
Understanding current and past Rasna Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Rasna Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Rasna Therapeutics' assets may result in an increase in income on the income statement.
Rasna Therapeutics Stock Summary
Rasna Therapeutics competes with Legacy Education, Apple, NVIDIA, Microsoft, and Amazon. Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 420 Lexington Avenue, |
| Benchmark | Dow Jones Industrial |
| Website | www.rasna.com |
| Phone | 646 396 4087 |
| Currency | USD - US Dollar |
Rasna Therapeutics Key Financial Ratios
Rasna Therapeutics' financial ratios allow both analysts and investors to convert raw data from Rasna Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Rasna Therapeutics over time and compare it to other companies across industries.| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Number Of Employees | 13 | |||
| Beta | -57.77 | |||
| Z Score | 84.6 |
Rasna Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rasna Therapeutics's current stock value. Our valuation model uses many indicators to compare Rasna Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rasna Therapeutics competition to find correlations between indicators driving Rasna Therapeutics's intrinsic value. More Info.Rasna Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rasna Therapeutics' earnings, one of the primary drivers of an investment's value.Rasna Therapeutics Systematic Risk
Rasna Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rasna Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Rasna Therapeutics correlated with the market. If Beta is less than 0 Rasna Therapeutics generally moves in the opposite direction as compared to the market. If Rasna Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rasna Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rasna Therapeutics is generally in the same direction as the market. If Beta > 1 Rasna Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.